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What is already known on this topic?
 ► Various prednisolone formulations are frequently 
used to treat asthma-like symptoms in children; 
the potential differences in bioequivalence between 
these formulations have never been examined.
 ► Pharmacokinetic studies have traditionally been 
burdensome for the paediatric population due to nu-
merous blood samples.
 ► It is important to study the acceptability of paedi-
atric formulations, since manipulating medicine or 
introducing different formulations may diminish or 
enhance tolerability.
What this study hopes to add?
 ► Paediatric bioequivalence data on prednisolone oral 
solution, crushed tablets and orodispersible tablets 
compared with whole tablets.
 ► Prednisolone concentration data are collected us-
ing saliva samples, validated with plasma samples 
if the patient has an intravenous access for clinical 
purposes.
 ► Acceptability data on different prednisolone formula-
tions using a modified Wong-Baker face scale.
AbstrACt
Introduction One in three Danish children under 
3 years of age experience asthma-like symptoms, and 
one-third will later be diagnosed with asthma. Oral 
prednisolone is used in various formulations to treat 
acute asthma. However, the potential differences in 
bioequivalence between these formulations have never 
been examined in children despite interchangeable use in 
clinical practice.
Methods and analysis An open-label, randomised, 
two-treatment cross-over trial investigating the 
bioequivalence of different prednisolone formulations in 
children with airway disease.
The included patients (6 months–11 years of age) are 
admitted to the Department of Paediatric and Adolescent 
Medicine Nordsjællands University Hospital, Hillerød, with 
asthma or asthma-like symptoms.
The primary objective is to assess the bioequivalence 
between different prednisolone formulations herein area 
under the concentration time curve, Cmax and Tmax using 
saliva samples. The secondary objectives are to evaluate 
tolerability (five-point face scale), adverse events and 
severity of the disease. If the patient has an intravenous 
access for other purposes, the saliva samples will be 
validated with plasma samples.
A total of 66 evaluable patients are needed according to 
European Medicines Agency Guideline on bioequivalence.
Ethics and dissemination Traditional pharmacokinetic 
trials are burdensome due to the extent of blood samples 
necessary to capture the time-dependant drug profile. 
Saliva sampling is far more acceptable for paediatric 
patients. In addition, this trial adheres to standard dosing 
strategies. No additional venepunctures are performed, and 
no additional prednisolone doses are administered.
Guidelines for paediatric bioequivalence trials are 
warranted.
trial registration number The Danish Medicines 
Agency EudraCT: 2017-003590-33, The Ethics Committee 
case no: H-17027252, and the Danish Data Protection 
Agency: BFH-2017–103, I-Suite no.: 05935.
IntroduCtIon
One in three Danish children under 3 years 
of age experience asthma-like symptoms, 
and one-third will later be diagnosed with 
asthma.1 Therapeutic management of acute 
asthma-like symptoms in infants and children 
has been repeatedly discussed.2 Oral gluco-
corticoids are frequently added to inhaled 
beta-2-agonist if the patient does not respond 
to the initial treatment. However, no thera-
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no clinical biomarker has been deveopled to asses effi-
cacy.3
Furthermore, in Denmark, only intravenous formu-
lations and prednisolone or hydrocortisone tablets are 
licenced for patients <18 years of age.4 Infants and chil-
dren who are unable or unwilling to swallow a tablet 
or where dosing is based on body weight are urged to 
use either an extemporaneous oral liquid formulation, 
crushed or split tablets. Splitting tablets may lead to dose 
inaccuracy, and in one study, crushing hydrocortisone 
tablets lead to therapeutic failure.5 Extemporaneous 
formulations are not subject to randomised controlled 
trials as licenced formulations and bioequivalence (BE) 
are not determined between different formulations with 
the same active ingredience.5 6 Moreover, the paediatric 
population is a heterogeneous group of patients ranging 
from premature neonates to adolescents. The wide phys-
ical and developmental differences influence both phar-
macokinetic (PK) and pharmacodynamic parameters. 
These issues are generally poorly studied.7
BE studies compare both the rate (the time to Cmax-
=Tmax) and extent of absorption (area under the 
concentration time curve (AUC) of various drug formu-
lations. Regulatory guidelines on BE state that two treat-
ments are not different from one another if the 90% CI 
of the ratio of a log-transformed exposure measure (AUC 
and/or Cmax) falls within the range of 80%–125%.8
To date, one BE study with prednisolone have been 
performed in healthy adults.9 Francisco et al9 examined 
AUC, Tmax and Cmax of five commercially oral pred-
nisone tablets compared with one reference solution in 
18 healthy adults.9 No statistically significant differences 
were found between the tablets. Non-significant varia-
tions were seen between the solution and tablets except 
for Tmax, which was 0.53 and 1.2–1.7 hours, respectively.9 
A bioavailability study from Georgitis et al10 compared 
liquid prednisone, prednisone tablet and intravenous 
prednisolone10 and found that the AUC for liquid and 
tablet were significantly different.10 No studies have been 
performed in a target patient population, taking into 
consideration factors such as comorbidities, comedica-
tion and physiological factors including first pass metab-
olism, gastric pH and bacterial flora, which are highly 
relevant in infants and children.
However, traditional PK trials are burdensome due to 
the extent of blood samples, necessary to capture the 
time-dependant drug profile. New non-invasive methods 
such as saliva sampling are far more acceptable for paedi-
atric patients. In a recent adult population PK study, free 
prednisolone concentrations correlated well with sali-
vary concentrations.11 The same study set-up were later 
applied in a population PK model in paediatric patients 
(n=104) with nephrotic syndrome.12 None of the studies 
included more than one formulation.
The importance to study the acceptability of paediatric 
formulations has recently been endorsed since manip-
ulating medicine or introducing different formulations 
may diminish or enhance tolerability.13 Acceptability of 
medicines influence adherence to therapeutic regimens 
and outcomes. No validated method to access accept-
ability of paediatric medicine exists, and many different 
scales have been used most commonly hedonic face 
scales or visual analogue scale (VAS).13 Lucas-Bouwman 
et al14 investigated the acceptability of prednisolone oral 
solution and crushed tablets using VAS taste scale. The 
oral solution obtained the best score and no vomiting was 
observed in the oral solution treatment group compared 
with 23% in the other group. Aljebab et al15 showed that 
dexamethasone elixir was more palatable than predniso-
lone tablets, soluble tablets and syrup using af five-point 
hedonic face scale in children below 12 years of age in the 
UK and Saudi Arabia.15 Prednisolone syrup and soluble 
tablets caused less vomiting than tablets.15
objECtIvEs
We aim to investigate the bioeqvalence of different pred-
nisolone formulations in three different age-groups and 
secondary to investigate the tolerability, adverse events, 
severity of the disease and validation of saliva samples, 
table 1.
MEthods And AnAlysIs
A single-centre, randomised, open-label two-treatment 
cross-over design.
Children with asthma or asthma-like symptoms 
admitted to the Department of Paediatric and Adolescent 
Medicine, Nordsjællands University Hospital, Hillerød, 
are eligible for inclusion.
Population
Eligibility criteria are described in table 2. Patients are 
stratified by age in accordance with European Medi-
cines Agency (EMA) guidelines into three groups, 
that is, 6–23 months, 2–5 years and 6–11 years.16 Two 
different formulations of prednisolone as 1 mg/kg/day 
will be administered to each participant for two consec-
utive days (figure 1). A control group of school children 
age 6–11 years will receive whole tablets. In total, four 
different formulations will be investigated (see figure 1). 
All trial medicine is labelled, packed and distributed by 
the Regional Pharmacy in accordance with GMP Annex 
13,17 except the high-strength oral prednisolone solu-
tion 20 mg/mL, which is ‘ward medicine’ and does not 
require special labelling. A separate accountancy is kept 
for each formulation of prednisolone.
Patient involvement
Patients were not directly involved in the design of this 
study.
saliva samples
The primary and secondary outcomes are assessed at 
predefined time points shown in table 3 and figure 1. 
Patients are randomised to one of two sampling groups, 
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Table 1 Primary and secondary objectives and outcomes in the POP child trial
Objectives and outcomes
Primary objective Primary outcome
To investigate the bioequivalence of different prednisolone 
formulations, that is, crushed tablets, oral solution and 
orodipersible tablets to characterise their bioequivalence 
compared with standard whole tablets (controls). Herein 
compare the AUC, Cmax and Tmax.
Concentration time data on prednisolone concentration 
measured in saliva to determine AUC, Tmax and Cmax.
Secondary objective Secondary outcome
1. Acceptability of different formulations assessed by 
patient preferences and number of attempts
2. Adverse events.
3. Modified Pulmonary Index Score (MPIS) and Paediatric 
Early Warning Score (PEWS).
4. Validation of the saliva samples using plasma samples.
1. Acceptability of different formulations measured by a 
modified Wong-Baker face scale (see figure 2).
2. Adverse events registration.
3. MPIS and PEWS score at administration time for doses 1 and 
2.
4. Concentration-time data on prednisolone concentration 
measured in plasma to determine AUC, Tmax and Cmax
AUC, area under the concentration time curve.
Table 2 Inclusion and exclusion criteria for the POP child 
trial
Inclusion and exclusion criteria for the POP child trial
Inclusion criteria Exclusion criteria
Children from 6 months 
to 11 years of age, both 
gender, all ethnicities.
Unable to comply with trial 
procedures, for example, 
inability to swallow tablets, not 
cooperative for saliva sampling 
and so on.
Asthma-like symptoms or 
asthma.
Admitted to the paediatric 
or emergency department.




Menarche or testis volume 
>4 mL (evaluated in children 
above 7 years of age).
Informed written consent 




Non-compliance with the 
given formulations after 
three attempts.
POP, Pharmacokinetics of prednisolone.
the basis of a previous study.12 Each child will follow 
the same time schedule for both doses. The samples 
will be collected using the SalivaBio Children’s Swab 
and the SalivaBio Oral Swab (exclusively from Salimet-
rics, State College, Pennsylvania, USA), synthetic swabs 
specifically designed to improve volume collection and 
increase participant compliance. Saliva will be removed 
from the swabs by centrifuge (15 min at 2500 rpm) and 
stored in cryovials at −20 ᵒC for maximum 2 weeks and 
hereafter at −80°C until analysis. Concentrations of 
prednisolone and its inactive metabolite prednisone 
will be determined by liquid chromatography with mass 
spectrometric detection. The assay is validated according 
to the EMA guideline ‘Guideline on bioanalytical 
method validation’ (EMEA/CHMP/EWP/192217/2009 
Rev. 1 Corr. 2**Committee for Medicinal Products for 
Human Use). Analyses are performed in accordance 
with ISO 15189. Concentrations will be determined in 
10 µL saliva or plasma. In the latter case, both total and 
unbound concentrations will be determined. The lower 
limit of quantification is 2 ng/mL for both compounds. 
Saliva samples are non-invasive samples and are consid-
ered a painless low-risk procedure.16 Saliva sampling of 
prednisolone and subsequent analysis has recently been 
performed in children with median 4.6 years of age using 
Salivette equipment.12 As this trial includes children from 
6 months of age, we chose the Salimetrics equipment. If 
any child has a cubital intravenous access at inclusion, 
additional blood samples will be taken time equivalent 
to the saliva samples. In order to assess plasma predni-
solone for validation of the saliva samples. No additional 
venepunctures will be made.
sample size
The number of subjects required for a BE study depends 
on the expected deviation between formulations.18 
Because of limited data on prednisolone PKs and BE 
of different formulations, sample size calculation is 
not feasible. In accordance with the EMA guideline on 
the investigation of BE,8 the number of subjects to be 
included in a study should preferably be based on sample 
size calculations and not be less than 12. To account for 
drop-outs, 14 patients were allocated to each formulation 
in the three different age groups and the control group 
(a total of 77 patients) (figure 1). The optimal number of 
participants is 66 evaluable patients.
randomisation
The participants are randomised in the REDCap soft-
ware ( www. project- redcap. org). The REDCap software 
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Figure 1 In total, four investigational medical products (IMPs) are used: ‘Prednisolon DAK’ whole tablets, ‘Prednisolon DAK’ 
crushed tablets (5 or 25 mg), extemporaneous prednisolone oral solution and SOLUPRED orodispersible tablets (5 or 20 mg 
imported from France). The oral solution exists in two strengths, that is, 5 mg/mL (for children below 10 kg) and 20 mg/mL (for 
children above 10 kg).
the Capital Region in Denmark. The randomisation list is 
uploaded in REDCap and is blinded to everyone except a 
third person, who generates the list and has no other role 
in the trial. The participants are age stratified and will 
be block randomised to ensure an equal amount in each 
subgroup (figure 1). The child will receive a REDCap 
generated ID number including a combination of letters 
describing the formulations to be given. Administration 
of prednisolone is done open-label by the project staff or 
paediatric nurses.
statistical methods
The AUC(0 t) and Cmax parameters will be calculated 
using single subject compartmental modelling. Actual 
time of sampling will be used in the estimation of the 
PK parameters. The assessment of BE will be based on 
90% CIs for the ratio of the population geometric means 
(test/reference), with the null hypothesis of BE at the 
5% significance level (acceptance interval of 80.00%–
125.00%)8 using ANOVA or t-test. The comparison 
between the different age groups will be done in a step-
wise manner, initially comparing the various subpopula-
tion, for example, the 6–23 months old. If these data are 
comparable, we will pool the data and compare with the 
older age groups. The oldest age group will only then 
serve as control group across age population. If the data 
do not show BE, the bioavailability data will be reported 
separately for each age group.
The person responsible for the statistical analysis of 
saliva samples will be blinded to the formulations given. 
Due to the limited wash-out period, a test for carry-over 
will be addressed by examination of the pretreatment 
plasma concentrations in period 2.
All patients who fulfils the eligibility criteria and have 
had at least one saliva sample taken will be analysed for 
demographic and baseline data. In the PK modelling, all 
saliva samples will be included. If any predose concentra-
tion is more than 5% of Cmax, this will be reported and 
handled appropriately in the final analysis.
Ethics and dissemination
Before prednisolone treatment is initiated, a patient infor-
mation sheet is given to eligible patients and the trial is 
explained to their parents. Parents will have a minimum 
of 15 min to consider the consent, because treatment 
should not be unnecessarily delayed. Informed consent 
will be granted by parents or legal guardian, as all chil-
dren are below 15 years of age. If one of the parents is 
not present, a written authority can be used. The consent 
process will be conducted by an investigator with training 
and experience with minors. The collected material is 
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Table 3 The table illustrates the different trial activities.
Visit
Screening
Baseline 1. dose 2. dose








timing of saliva 
samples
See individualised 
timing of saliva 
samples
Same sampling times 
as the saliva samples
Eligibility
  Informed consent x
  Inclusion and exclusion criteria x x
  Information to parents x x     
Other measurements
  Other medicine X* X* x
  MPIS/PEWS X* X* x
  Assessment of adverse events x x x
  Weight X* X* X*
Effect parameters
  Prednisolone concentrations 
measured in saliva samples
x x x x†
Secondary parameters
  Tolerability x x
*Will share the same value or registration.
†Blood samples in addition to saliva samples.
MPIS, Modified Pulmonary Index Score; PEWS, Paediatric Early Warning Score.
safety
Despite a large therapeutic index, it is important that 
all glucocorticoids are administered in the lowest effec-
tive dose as possible, since a considerable number 
of dose-dependent adverse drugs reactions (ADRs) 
are well described.4 A recent review found that the 
most frequent ADRs associated with short course oral 
corticosteroids (<14 days) in children were vomiting, 
changes in behavoiur and sleep disturbances with 
incidence rates of 5.4%, 4.7% and 4.3%, respectively. 
Increased susceptability to infection were one of the 
serious ADRs ocurring in up to 1% of the children.19
trial limitations
Alterations have been made in this trial compared 
with a classic BE trial to adapt to the relevant popu-
lation. There are no existing guidelines for paediatric 
BE trials. A guideline is warranted since paediatric BE 
trials must be pragmatic in order to adapt to the paedi-
atric population and to be conducted ethically.
Optimally, a randomised, two-period/three-period, 
two-sequence/three-sequence single-dose cross-over 
design would be used for healthy adults. This trial is a 
single-dose study performed during admission, limiting 
the possible number of doses/formulations per 
patient, with a theoretical washout period of 24 hours, 
as prednisolone is dosed once daily. The half-life of 
prednisolone is 2.5±0.5 hours,20 21 and 24 hours should 
be enough time to ensure drug concentrations below 
quantification. However, as a precaution, predose 
samples are collected if prednisolone has been admin-
istered the day before inclusion. The saliva samples will 
be measured in 11 or 12 hours, respectively, which will 
be within five half-lives for many patients. Late night 
samples will be more difficult to collect if the partici-
pants are asleep and some might not be collected due 
to patient and parent preferences.
The reference product in this trial is whole tablets, 
since intravenous glucocorticoids are mainly used for 
severe asthma. The effect of fasting and fed are not 
within the scope of this trial since no effect on bioavail-
ability was found in prednisolone whole tablets.4 To 
avoid prednisolone leftovers in the mouth, all children 
will be given water after administration of trial medi-
cine. There can be differences in which the hedonic 
face scale is presented to the child, and this can be of 
some limitation (figure 2). Only 2–5 persons will include 
participants in this trial, minimising the variability.
We expect to have some dropouts due to: (1) non-com-
pliance with the formulations and (2) due to earlier 
than expected discharge. In the control group with 
whole tablets data suggest that about 91% of 6-year-old 
children can swallow a 7 mm tablet.13 The whole tablets 
are 8 mm (5 mg) and 10 mm (25 mg) but with break 
lines. We chose to include two strengths of prednis-
olone oral solution, to make sure the volumes were 
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Figure 2 Modified Wong-Baker face scale to access tolerability of trial medicine. Self-reported tolerability of the medicine 
is collected from children older than 6 years of age. The options A–E is read aloud neutrally to the child. For children below 6 
years of age, a parent is asked to evaluate the tolerability. Vomiting is registered separately but is included in the face scale as 
F.
only during daytime could give some recruitment bias; 
however, as this is primarily a PK trial, we do not expect 
this to influence the results. This trial is conducted at 
one site which can limit the generalisability but will 
enhance the consistency.
trial registration
This trial is an investigator-initiated trial from the 
Department of Clinical Pharmacology, Bispebjerg 
Hospital and the Department of Paediatric and Adoles-
cent Medicine, Nordsjællands Hospital, Hillerød. The 
trial is approved by the Danish Medicines Agency 
EudraCT: 2017-003590-33, the Ethics Committee 
case no: H-17027252 and the Danish Data Protection 
Agency: BFH-2017–103, I-Suite no.: 05935. The trial is 
monitored by the GCP-unit Copenhagen University.
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